Cardiovascular Outcomes with Another GLP-1 Receptor Agonist

Efpeglenatide, which is not yet U.S. FDA-approved, lowered adverse cardiovascular event rates.

New glucagon-like peptide-1 (GLP-1) receptor agonists keep coming, with particular focus on their cardiovascular (CV) and renal effects in patients with type 2 diabetes. In this industry-sponsored randomized trial, the GLP-1 agonist efpeglenatide, injected once weekly, was compared with placebo in 4000 patients with type 2 diabetes (mean age, 65; mean glycosylated hemoglobin [HbA_1c], 8.9%). All participants had either prior CV disease or impaired renal function (glomerular filtration rate [GFR], 25–60 mL/minute/1.73 m²) plus a CV risk factor, and most were taking other drugs for diabetes and CV disease prevention. (Note: Efpeglenatide is not yet U.S. FDA-approved.)

During median follow-up of 1.8 years, incidence of a major adverse CV event w…

Reviewing Author

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Cardiovascular Outcomes with Another GLP-1 Receptor Agonist

Topics

Reviewing Author